Patents Assigned to GENOSCIENCE
-
Patent number: 11261189Abstract: 2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments are disclosed. The compounds are useful as a medicament in treating and/or decreasing the severity and/or progression and/or preventing fibrosis and/or related diseases, or for use as a medicament in treating, decreasing the severity and/or progression of and/or preventing autophagy and/or related diseases, for inhibiting autophagy flux, and for inhibiting cathepsins B (CTSB), L (CTSL) and/or D (CTSD) and/or related diseases.Type: GrantFiled: August 1, 2019Date of Patent: March 1, 2022Assignee: GENOSCIENCE PHARMAInventors: Philippe Halfon, Firas Bassissi, Sonia Brun, Jérôme Courcambeck, Madani Rachid
-
Patent number: 10722505Abstract: The present invention relates to novel 2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments. The active compounds of the present invention are useful for the treatment and prevention of proliferative neoplastic and non-neoplastic diseases.Type: GrantFiled: October 26, 2015Date of Patent: July 28, 2020Assignee: GENOSCIENCE PHARMAInventors: Firas Bassissi, Antoine Beret, Sonia Brun, Jérôme Courcambeck, Clarisse Dubray, Gregory Nicolas, Philippe Halfon
-
Patent number: 10577362Abstract: This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein which exhibit strong inhibition effects on various cancer cell lines. The compounds disclosed herein are useful for the treatment of proliferative diseases, including neoplastic diseases such as cancer and non-neoplastic disorders such as rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing compounds of Formula I and at least one carrier, diluent or excipient and optionally one or more additional therapeutically active agents, including anticancer agents. This application also discloses methods for treating a proliferative disease, including neoplastic diseases such as cancer and non-neoplastic disorders such as rheumatoid arthritis.Type: GrantFiled: May 4, 2017Date of Patent: March 3, 2020Assignee: GENOSCIENCE PHARMAInventors: Sonia Brun, Antoine Beret, Firas Bassissi, Philippe Halfon, Jérôme Courcambeck
-
Publication number: 20190144437Abstract: This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein which exhibit strong inhibition effects on various cancer cell lines. The compounds disclosed herein are useful for the treatment of proliferative diseases, including neoplastic diseases such as cancer and non-neoplastic disorders such as rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing compounds of Formula I and at least one carrier, diluent or excipient and optionally one or more additional therapeutically active agents, including anticancer agents. This application also discloses methods for treating a proliferative disease, including neoplastic diseases such as cancer and non-neoplastic disorders such as rheumatoid arthritis.Type: ApplicationFiled: May 4, 2017Publication date: May 16, 2019Applicant: GENOSCIENCE PHARMAInventors: Sonia BRUN, Antoine BERET, Firas BASSISSI, Philippe HALFON, Jérôme COURCAMBECK
-
Patent number: 10179770Abstract: The invention provides quinoline derivatives, their manufacture, pharmaceutical compositions containing them, and their use as medicaments. The active compounds of the present invention are useful for the treatment of proliferative neoplastic and non-neoplastic diseases.Type: GrantFiled: March 13, 2014Date of Patent: January 15, 2019Assignee: GENOSCIENCE PHARMAInventors: Jerome Courcambeck, Philippe Halfon, Firas Bassissi, Sonia Brun, Gregory Nicolas, Antoine Beret, Serge Petit, Claire Camus, Jean Pierre Nallet
-
Patent number: 8987302Abstract: Methods of treating a hepatitis C virus (HCV) related disease, such as HCV infections in subjects non-responsive to anti-HCV therapy, are described herein, comprising administering to the subject a therapeutically effective amount of hydroxychloroquine. An antiviral agent may be co-administered with the hydroxychloroquine. Methods utilizing synergistic combinations of hydroxychloroquine and an antiviral agent are disclosed. Further disclosed are compositions comprising hydroxychloroquine and an antiviral agent, as well as hydroxychloroquine and uses thereof for the treatment of a hepatitis C virus (HCV) related disease.Type: GrantFiled: December 26, 2012Date of Patent: March 24, 2015Assignees: Panmed Ltd., Genoscience Pharma SASInventor: Philippe Halfon
-
Patent number: 8729014Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HCV in human patients or other animal hosts.Type: GrantFiled: October 28, 2011Date of Patent: May 20, 2014Assignees: RFS Pharma, LLC, GenoscienceInventors: Jerome Courcambeck, Philippe Halfon, Mourad Bouzidi, Steven J. Coats, Richard Anthony Whitaker
-
Patent number: 8575195Abstract: Methods of treating a hepatitis C virus (HCV) related disease, such as HCV infections in subjects non-responsive to anti-HCV therapy, are described herein, comprising administering to the subject a therapeutically effective amount of hydroxychloroquine. An antiviral agent may be co-administered with the hydroxychloroquine. Methods utilizing synergistic combinations of hydroxychloroquine and an antiviral agent are disclosed. Further disclosed are compositions comprising hydroxychloroquine and an antiviral agent, as well as hydroxychloroquine and uses thereof for the treatment of a hepatitis C virus (HCV) related disease.Type: GrantFiled: March 15, 2013Date of Patent: November 5, 2013Assignees: Panmed Ltd., Genoscience Pharma SASInventor: Philippe Halfon
-
Publication number: 20130202556Abstract: Methods of treating a hepatitis C virus (HCV) related disease, such as HCV infections in subjects non-responsive to anti-HCV therapy, are described herein, comprising administering to the subject a therapeutically effective amount of hydroxychloroquine. An antiviral agent may be co-administered with the hydroxychloroquine. Methods utilizing synergistic combinations of hydroxychloroquine and an antiviral agent are disclosed. Further disclosed are compositions comprising hydroxychloroquine and an antiviral agent, as well as hydroxychloroquine and uses thereof for the treatment of a hepatitis C virus (HCV) related disease.Type: ApplicationFiled: March 15, 2013Publication date: August 8, 2013Applicants: Genoscience Pharma SAS, Panmed Ltd.Inventor: Philippe Halfon
-
Publication number: 20130121965Abstract: Methods of treating a hepatitis C virus (HCV) related disease, such as HCV infections in subjects non-responsive to anti-HCV therapy, are described herein, comprising administering to the subject a therapeutically effective amount of hydroxychloroquine. An antiviral agent may be co-administered with the hydroxychloroquine. Methods utilizing synergistic combinations of hydroxychloroquine and an antiviral agent are disclosed. Further disclosed are compositions comprising hydroxychloroquine and an antiviral agent, as well as hydroxychloroquine and uses thereof for the treatment of a hepatitis C virus (HCV) related disease.Type: ApplicationFiled: December 26, 2012Publication date: May 16, 2013Applicants: Genoscience Pharma SAS, Panmed Ltd.Inventors: Panmed Ltd., Genoscience Pharma SAS
-
Publication number: 20120129765Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HCV in human patients or other animal hosts.Type: ApplicationFiled: October 28, 2011Publication date: May 24, 2012Applicants: GENOSCIENCE, RFS Pharma, LLCInventors: Jerome Courcambeck, Philippe Halfon, Mourad Bouzidi, Steven J. Coats, Richard Anthony Whitaker
-
Publication number: 20060142204Abstract: The present invention relates to novel hepatitis C virus (“HCV”) protease inhibitors or other flavivirus protease inhibitors having the general structure (I) or (II), pharmaceutical compositions containing one or more such inhibitors, methods for preparing such inhibitors, uses of these compounds to treat hepatitis C and related disorders together with their use for their activity towards NS3 serine protease, intermediary compounds for the method of preparation of said compounds and screening methods. The invention specifically discloses novel chemical compounds as inhibitors of the HCV serine protease.Type: ApplicationFiled: October 9, 2003Publication date: June 29, 2006Applicant: GENOSCIENCEInventors: Philippe Halfon, Chalom Sayada, Jean-Marc Feryn, Regis Perbost, Frederic Garzino, Michel Camplo, Jerome Courcambeck, Gerard Pepe